New kidney drug tested in patients with liver issues
NCT ID NCT06674915
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed Phase 1 study looked at how the drug HRS-5965 behaves in people with mild or moderate liver impairment compared to those with normal liver function. Twenty-four adults took a single 50 mg dose of the drug. The goal was to measure drug levels in the blood and check for side effects, not to treat the kidney disease itself.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HRS-5965
- What this could lead to
- If successful, this study could help determine safe dosing of HRS-5965 for people with liver problems, potentially leading to better treatment options for kidney diseases.
- What could go wrong
- This is an early Phase 1 study with only 24 people, focused on safety and drug levels, not on treating the disease. Results may not predict effectiveness or apply to broader populations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COMPLEMENT MEDIATED PRIMARY OR SECONDARY GLOMERULAR DISEASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital of Suzhou University
Suzhou, Jiangsu, 215008, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Liver health and drug processing: a closer look at casdatifan
- Liver function may change how belapectin works in the body
- Liver function may change how ammoxetine works
- Liver function may affect how Weight-Loss drug petrelintide works
- Liver health may change how a promising cancer drug works in the body
- Liver health may change how body handles inhaled lung drug